(Pexels)
Of all the investable sectors and industries, one of the top-performing over the past few months is biotechnology. Since its March low (18th), the SPDR Biotech ETF (XBI) has risen about 75% as investors speculate on virus treatment and vaccine rumors.
Understandably, many investors expect biotechnology companies to benefit greatly from the current situation as governments pour money into the sector. The last U.S. stimulus bill (worth over $2T) placed $8.3B in money to be spent on virus research and response (just over $3B directly into research). Of